An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Trial Profile

An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Eftrenonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms B-YOND
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 29 Nov 2017 This trial has been completed in Belgium (End Date: 2017-11-01)
    • 27 Nov 2017 According to a Bioverativ media release, based on interim data from the B-YOND trial and final data from the Kids B-LONG pediatric study the U.S. Food and Drug Administration (FDA) has approved updated labeling for ALPROLIX the leading extended half-life therapy for the treatment of adults and children with hemophilia B.
    • 18 Nov 2017 This trial has been completed in Sweden (End Date: 2017-11-01)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top